JAMES PATRINELY to Ipilimumab
This is a "connection" page, showing publications JAMES PATRINELY has written about Ipilimumab.
Connection Strength
0.642
-
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 06; 22(6):836-847.
Score: 0.185
-
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. J Immunother Cancer. 2021 05; 9(5).
Score: 0.185
-
Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. Cancer. 2020 08 01; 126(15):3448-3455.
Score: 0.174
-
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. Eur J Cancer. 2022 11; 176:121-132.
Score: 0.051
-
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply. Lancet Oncol. 2021 08; 22(8):e343-e344.
Score: 0.047